Overall, the properties of cationic liposomes, such as lipid composition, surface modification, and size, influence their performance and potential applications [79]
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
however, according to another study, after application of ICH-recommended overall illumination, only 4.5 % of the drug was degraded
For immune-modulating peptides, see LL-37 or Thymosin Alpha-1
A blend often indicates a more advanced formula